Simon Hsu1,2, Leila R Zelnick3,2, Yvonne S Lin4, Cora M Best2,5, Bryan Kestenbaum3,2,6, Kenneth E Thummel4, Lynn M Rose7, Andrew N Hoofnagle2,5, Ian H de Boer3,2,8. 1. Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington sihsu@uw.edu. 2. Kidney Research Institute, University of Washington, Seattle, Washington. 3. Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington. 4. Department of Pharmaceutics, University of Washington, Seattle, Washington. 5. Department of Laboratory Medicine, University of Washington, Seattle, Washington. 6. Department of Epidemiology, University of Washington, Seattle, Washington. 7. Department of Pharmacy, University of Washington, Seattle, Washington. 8. Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
Abstract
BACKGROUND: Conversion of 25-hydroxyvitamin D (25[OH]D) to the active form of vitamin D occurs primarily in the kidney. Observational studies suggest 25(OH)D clearance from the circulation differs by kidney function and race. However, these potential variations have not been tested using gold-standard methods. METHODS: We administered intravenous, deuterated 25(OH)D3 (d-25[OH]D3) in a pharmacokinetic study of 87 adults, including 43 with normal eGFR (≥60 ml/min per 1.73 m2), 24 with nondialysis CKD (eGFR <60 ml/min per 1.73 m2), and 20 with ESKD treated with hemodialysis. We measured concentrations of d-25(OH)D3 and deuterated 24,25-dihydroxyvitamin D3 at 5 minutes and 4 hours after administration, and at 1, 4, 7, 14, 21, 28, 42, and 56 days postadministration. We calculated 25(OH)D clearance using noncompartmental analysis of d-25(OH)D3 concentrations over time. We remeasured 25(OH)D clearance in a subset of 18 participants after extended oral vitamin-D3 supplementation. RESULTS: The mean age of the study cohort was 64 years; 41% were female, and 30% were Black. Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02). After adjustment for age, sex, race, and estimated blood volume, lower eGFR was associated with reduced 25(OH)D clearance (β=-17 ml/d per 10 ml/min per 1.73 m2 lower eGFR; 95% CI, -21 to -12). Black race was associated with higher 25(OH)D clearance in participants with normal eGFR, but not in those with CKD or kidney failure (P for interaction=0.05). Clearance of 25(OH)D before versus after vitamin-D3 supplementation did not differ. CONCLUSIONS: Using direct pharmacokinetic measurements, we show that 25(OH)D clearance is reduced in CKD and may differ by race. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease (CLEAR), NCT02937350; Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation (CLEAR-PLUS), NCT03576716.
BACKGROUND: Conversion of 25-hydroxyvitamin D (25[OH]D) to the active form of vitamin D occurs primarily in the kidney. Observational studies suggest 25(OH)D clearance from the circulation differs by kidney function and race. However, these potential variations have not been tested using gold-standard methods. METHODS: We administered intravenous, deuterated 25(OH)D3 (d-25[OH]D3) in a pharmacokinetic study of 87 adults, including 43 with normal eGFR (≥60 ml/min per 1.73 m2), 24 with nondialysis CKD (eGFR <60 ml/min per 1.73 m2), and 20 with ESKD treated with hemodialysis. We measured concentrations of d-25(OH)D3 and deuterated 24,25-dihydroxyvitamin D3 at 5 minutes and 4 hours after administration, and at 1, 4, 7, 14, 21, 28, 42, and 56 days postadministration. We calculated 25(OH)D clearance using noncompartmental analysis of d-25(OH)D3 concentrations over time. We remeasured 25(OH)D clearance in a subset of 18 participants after extended oral vitamin-D3 supplementation. RESULTS: The mean age of the study cohort was 64 years; 41% were female, and 30% were Black. Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02). After adjustment for age, sex, race, and estimated blood volume, lower eGFR was associated with reduced 25(OH)D clearance (β=-17 ml/d per 10 ml/min per 1.73 m2 lower eGFR; 95% CI, -21 to -12). Black race was associated with higher 25(OH)D clearance in participants with normal eGFR, but not in those with CKD or kidney failure (P for interaction=0.05). Clearance of 25(OH)D before versus after vitamin-D3 supplementation did not differ. CONCLUSIONS: Using direct pharmacokinetic measurements, we show that 25(OH)D clearance is reduced in CKD and may differ by race. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease (CLEAR), NCT02937350; Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation (CLEAR-PLUS), NCT03576716.
Authors: M A Tryfonidou; M A Oosterlaken-Dijksterhuis; J A Mol; T S G A M van den Ingh; W E van den Brom; H A W Hazewinkel Journal: Am J Physiol Endocrinol Metab Date: 2002-11-19 Impact factor: 4.310
Authors: Anders H Berg; Camille E Powe; Michele K Evans; Julia Wenger; Guillermo Ortiz; Alan B Zonderman; Pirianthini Suntharalingam; Kathryn Lucchesi; Neil R Powe; S Ananth Karumanchi; Ravi I Thadhani Journal: Clin Chem Date: 2015-04-28 Impact factor: 8.327
Authors: Lu Wang; Yiqing Song; Joann E Manson; Stefan Pilz; Winfried März; Karl Michaëlsson; Annamari Lundqvist; Simerjot K Jassal; Elizabeth Barrett-Connor; Cuilin Zhang; Charles B Eaton; Heidi T May; Jeffrey L Anderson; Howard D Sesso Journal: Circ Cardiovasc Qual Outcomes Date: 2012-11-13
Authors: Ian H de Boer; Michael C Sachs; Michel Chonchol; Jonathan Himmelfarb; Andrew N Hoofnagle; Joachim H Ix; Robin A Kremsdorf; Yvonne S Lin; Rajnish Mehrotra; Cassianne Robinson-Cohen; David S Siscovick; Michael W Steffes; Kenneth E Thummel; Russell P Tracy; Zhican Wang; Bryan Kestenbaum Journal: Am J Kidney Dis Date: 2014-04-03 Impact factor: 8.860
Authors: Timothy Wong; Zhican Wang; Brian D Chapron; Mizuki Suzuki; Katrina G Claw; Chunying Gao; Robert S Foti; Bhagwat Prasad; Alenka Chapron; Justina Calamia; Amarjit Chaudhry; Erin G Schuetz; Ronald L Horst; Qingcheng Mao; Ian H de Boer; Timothy A Thornton; Kenneth E Thummel Journal: Drug Metab Dispos Date: 2018-01-17 Impact factor: 3.922
Authors: Cortney R Bosworth; Gregory Levin; Cassianne Robinson-Cohen; Andrew N Hoofnagle; John Ruzinski; Bessie Young; Stephen M Schwartz; Jonathan Himmelfarb; Bryan Kestenbaum; Ian H de Boer Journal: Kidney Int Date: 2012-05-30 Impact factor: 10.612
Authors: Simon Hsu; David K Prince; Kayleen Williams; Norrina B Allen; Gregory L Burke; Andrew N Hoofnagle; Xiaohui Li; Kiang J Liu; Robyn L McClelland; Erin D Michos; Bruce M Psaty; Steven J Shea; Kenneth M Rice; Jerome I Rotter; David Siscovick; Russell P Tracy; Karol E Watson; Bryan R Kestenbaum; Ian H de Boer Journal: Am J Clin Nutr Date: 2022-03-04 Impact factor: 7.045
Authors: Colton W Sawyer; Stacey M Tuey; Raymond E West; Thomas D Nolin; Melanie S Joy Journal: Drug Metab Dispos Date: 2022-07-02 Impact factor: 3.579
Authors: Cora M Best; Leila R Zelnick; Kenneth E Thummel; Simon Hsu; Christine Limonte; Ravi Thadhani; Howard D Sesso; JoAnn E Manson; Julie E Buring; Samia Mora; I-Min Lee; Nancy R Cook; Georgina Friedenberg; Heike Luttmann-Gibson; Ian H de Boer; Andrew N Hoofnagle Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 6.134
Authors: Marciana L Laster; Bryce Rowan; Hua-Chang Chen; Tae-Hwi Schwantes-An; Xin Sheng; Peter A Friedman; T Alp Ikizler; Janet S Sinshiemer; Joachim H Ix; Katalin Susztak; Ian H de Boer; Bryan Kestenbaum; Adriana Hung; Sharon M Moe; Farzana Perwad; Cassianne Robinson-Cohen Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Mandy E Turner; Tyler S Rowsell; Christine A White; Martin Kaufmann; Patrick A Norman; Kathryn Neville; Martin Petkovich; Glenville Jones; Michael A Adams; Rachel M Holden Journal: Sci Rep Date: 2022-06-28 Impact factor: 4.996
Authors: Simon Hsu; Leila R Zelnick; Yvonne S Lin; Cora M Best; Bryan R Kestenbaum; Kenneth E Thummel; Andrew N Hoofnagle; Ian H de Boer Journal: J Steroid Biochem Mol Biol Date: 2021-12-22 Impact factor: 4.292